ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings
  • Abstract Number: 0085 • ACR Convergence 2024

    A Novel, Potent and Selective TLR7/8 Small Molecule Inhibitor Blocks TLR7/8 Pathway in the Presence of HCQ and Demonstrates Robust Preclinical Efficacy in Lupus Models

    Ching Shang1, Angie Hammond2, Yuanjiang Yu1, Bing Xia1, Yew Ann Leong1, Emily Chung1, zhiyu Huang1, Paqui Gonzalez Traves3, Wesley Minto1, Sunish Mohanan1, Hailing Zong1, Gundula Min-oo1, Stephen Ammann4, Eda Canales5 and Natasha Crellin3, 1Gilead Sciences, Foster City, CA, 2Gilead Sciences, Inc., Seattle, WA, 3Gilead, Foster City, CA, 4Gilead Sciences, Foster City, 5Gilead Sciences, San Mateo, CA

    Background/Purpose: Toll-like receptor 7, 8 and 9 (TLR7/8/9) are endosomal nucleic acid sensors that when aberrantly activated, induce Type I interferon (IFNα), proinflammatory cytokines, immune…
  • Abstract Number: 0089 • ACR Convergence 2024

    Single-Cell RNA Sequencing Outlines the Mechanisms of Vgll3-Driven Myofibroblasts Differentiation in Promoting Fibrosis in Cutaneous Lupus

    Mehrnaz Gharaee-Kermani, Allison Billi, Poulami Dey, Jacob Martens, Marisa Hildebrandt, J. Michelle Kahlenberg and Johann Gudjonsson, University of Michigan, Ann Arbor, MI

    Background/Purpose: Skin fibrosis is characterized by collagen deposition, fibro/myofibroblast accumulation, and extracellular matrix remodeling. Some subtypes of cutaneous lupus erythematosus (CLE), particularly discoid lupus erythematosus…
  • Abstract Number: 0136 • ACR Convergence 2024

    Demographic and Clinical Characteristics of Patients with SLE Across 5 Registries – the LupusNet Federated Data Network

    Federico Zazzetti1, Urbano Sbarigia2, William Giovanini3, Claire Blacketer4, Michel van Speybroeck5, Teresa A. Simon6, Guo Li3, Chetan S. Karyekar4, Reyhan Sonmez7, Manuel Ugarte-Gil8, RV, Gamboa-Cardenas9, Victor Pimentel-Quiroz10, Guillermo Pons-Estel11, Bernardo Pons-Estel12, Rosana Quintana13, Veronica Saurit14, ODIRLEI MONTICIELO15, Katiuzka Zuñiga Corrales16, Jorge Esquivel-Valerio17, Martin Rebella18, Cecilia Pisoni19, Francinne Machado Ribeiro20, Carlos Núñez-Álvarez21, Kaleb Michaud22, Patricia Katz23, Rangi Kandane-Rathnayake24, Eric Morand25, Worawit Louthrenoo26, Yi-Hsing Chen27, Jiacai Cho28, Laniyati Hamijoyo29, Shue Fen Luo30, Yeong-Jian Jan Wu30, Sandra Navarra31, Sargunan Sockalingam32, Masayoshi Harigai33, Zhuoli Zhang34, BMDB Basnayake35, Madelynn Chan36, Tsutomu Takeuchi37, Sang-Cheol Bae38, Fiona Goldblatt39, Sean O'Neill40, Kristine (Pek Ling) Ng41, Yih Jia Poh42, Nicola Tugnet43, Sunil Kumar44, Michael Tee45, Yoshiya Tanaka46 and Chak Sing. Lau47, Alberta Hoi48, Mandana Nikpour49, Mark Sapsford50, Íñigo Rúa-Figueroa50, José María Pego-Reigosa51, María Galindo-Izquierdo52, Jaime Calvo-Alén53, Antonio Fernández-Nebro54, Raúl Menor Almagro55 and Frederic Lavie56, 1Johnson & Johnson Innovative Medicine, Horsham, PA, PA, 2Johnson & Johnson Innovative Medicine, Brussels, Belgium, 3The Janssen Pharmaceutical Companies of Johnson & Johnson, Titusville, NJ, 4Janssen Research & Development, LLC, Spring House, PA, 5Janssen Pharmaceutica, Beerse, Belgium, 6Physicians Research Center, LLC, Toms River, NJ, 7EFOR-CVO Life Sciences Consultancy, Basel, Switzerland, 8Grupo Peruano de Estudio de Enfermedades Autoinmunes Sistémicas. Universidad Científica del Sur. Lima. Perú Servicio de Reumatología. Hospital Guillermo Almenara Irigoyen-EsSalud, Lima, Peru, 9Universidad Científica del Sur, Lima, Lima, Peru, 10Universidad Científica del Sur/Hospital Nacional Guillermo Almenara Irigoyen, Magdalena del Mar, Peru, 11Centro Regional de Enfermedades Autoinmunes y Reumáticas (GO-CREAR), Rosario, Argentina, ROSARIO, Santa Fe, Argentina, 12Centro Regional de Enfermedades Autoinmunes y Reumáticas (GO-CREAR), Rosario, Santa Fe, Argentina, 13Centro Regional de Enfermedades Autoinmunes y Reumáticas (GO-CREAR), Rosario, Argentina, 14hospital privado universitario de cordoba, Córdoba, Argentina, 15HOSPITAL DE CLINICAS DE PORTO ALEGRE, PORTO ALEGRE, Rio Grande do Sul, Brazil, 16Hospital Cayetano Heredia. Universidad Peruana Cayetano Heredia, Lima, Peru, 17Division of Rheumatology, University Hospital "Dr. Jose Eleuterio Gonzalez", Universidad Autonoma de Nuevo Leon, MONTERREY, Mexico, 18Unidad Enfermedades Autoinmunes Sistemicas, Clinica Medica C-Hospital de Clinicas, UDELAR Montevideo, Montevideo, Uruguay, 19CEMIC, Buenos Aires, Argentina, 20Hospital Universitario Pedro Ernesto, UERJ, Rio De Janeiro, Brazil, Rio de Janeiro, Brazil, 21Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, CDMX, Mexico, Mexico, Mexico, 22University of Nebraska Medical Center, Omaha, NE, 23University of California San Francisco, San Francisco, CA, 24Monash University, Clayton, Victoria, Australia, 25School of Clinical Sciences, Monash University, Melbourne, Victoria, Australia, 26Chiang Mai University, Chang Wat Chiang Mai, Thailand, 27Taichung Veterans General Hospital, Taichung, Taiwan (Republic of China), 28National University Hospital, Kent Ridge, Singapore, 29University of Padjadjaran, Sumedang Regency and Bandung, Indonesia, 30Chang Gung Memorial Hospital, Taoyuan City, Taiwan (Republic of China), 31University of Santo Tomas, Manila, Philippines, 32University of Malaya Medical Centre, Kuala Lumpur, Malaysia, 33Tokyo Women's Medical University, Tokyo, Japan, 34Peking University First Hospital, Beijing, China, 35Teaching Hospital, Kandy, Sri Lanka, 36Tan Tock Seng Hospital, Singapore, Singapore, 37Department of Internal Medicine, Keio University, Tokyo, Tokyo, Japan, 38Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, Republic of Korea, 39Flinders Medical Centre, Adelaide, Australia, 40Liverpool Hospital; Royal North Shore Hospital; University of New South Wales and the University of Sydney, Sydney, New South Wales, Australia, 41Health New Zealand Waitemata, Te Whatu Ora (North Shore Hospital), Auckland, New Zealand, 42SingHealth, Singapore, Singapore, 43Auckland District Health Board, Auckland, New Zealand, 44Health New Zealand Counties Manukau, Te Whatu Ora (Middlemore Hospital), Auckland, New Zealand, 45University of the Philippines, Manila, Philippines, 46Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Fukuoka, Japan, 47University of Hong Kong, Pok Fu Lam, Hong Kong, 48Monash Health, Monash University, Melbourne, AU, Melbourne, Victoria, Australia, 49The University of Sydney, Melbourne, Victoria, Australia, 50Middlemore Hospital, Auckland, New Zealand, 50Department of Rheumatology, Hospital Universitario Doctor Negrín, Las Palmas de Gran Canaria, Las Palmas GC, Spain, 6Galicia Health Service (SERGAS), Vigo, Spain, 52Department of Rheumatology, Hospital Universitario 12 de Octubre, Madrid, Spain, 53Department of Rheumatology, Hospital Araba, Vitoria, Pais Vasco, Spain, 54Department of Rheumatology, Hospital Universitario de Málaga, Málaga, Andalucia, Spain, 55Department of Rheumatology, Hospital Jerez de la Frontera, Jerez de la Frontera, Spain, 56Janssen Cilag Global Medical Affairs, Immunology Global Medical Affairs, Issy les Moulineaux, France

    Background/Purpose: Systemic lupus erythematosus (SLE) is an autoimmune disease with a broad range of clinical manifestations and a high unmet need across patient populations. Real-world…
  • Abstract Number: 0029 • ACR Convergence 2024

    Effect of Metformin on the Incidence of Total Knee Replacement: A Systematic Review and Meta-Analysis

    Syed Hasan1, Aali Furqan2, Afia Salman3, hira Khan4, Sarah Aslam5, Alishba Rizvi4, Hafsah Alim Ur Rahman3, Muhammad Ahmed Ali Fahim3, Madiha Salman3, Eman Ali3, Yumna Furqan6, Shanta bai7, Farah Yasmin8 and Muhammad Sohaib Asghar9, 1Dow University of Health Sciences, Karachi, PK., Karachi, Sindh, Pakistan, 2University of North Texas Health Science Center (UNT HSC), Texas, TX, 3Dow University of Health Sciences, Karachi, Pakistan, 4dow medical college, Karachi, Pakistan, 5Dow International Medical College, Karachi, Pakistan, 6Texas A&M School of Medicine, Dallas, TX, 7Liaquat National Hospital and Medical College, Karachi, Pakistan, 8Yale University School of Medicine, New Haven, CT 06511, U.S.A., New Haven, CT, 9AdventHealth, Sebring, FL

    Background/Purpose: Osteoarthritis (OA) is among the most common debilitating conditions, causing disability and pain in older adults. For end-stage OA, total knee replacement (TKR) is…
  • Abstract Number: 0024 • ACR Convergence 2024

    Trans-Signaling by Soluble CD14 Sensitizes Chondrocytes to Lipopolysaccharide Stimuli, Increasing Chondrocyte Inflammatory Responses

    Anna E. Rapp, Baofeng Hu and Carla Scanzello, University of Pennsylvania, Philadelphia, PA

    Background/Purpose: The understanding of osteoarthritis (OA) has evolved significantly over the past decade. Recently attention is being drawn to the role of pattern-recognition receptor (PRR)…
  • Abstract Number: 0095 • ACR Convergence 2024

    Expansion of Brain T Cell Subsets Outside of the Choroid Plexus in Murine Models of Neuropsychiatric Manifestations of Systemic Lupus Erythematosus

    Minjung Kim1, Cecilia Stumpf2, Hadijat Makinde1, Mohammad Khan1, Vanessa Rodriguez2, Tyler Therron2, Jeremy Tilstra3, Deborah Winter4 and Carla Cuda1, 1Northwestern University, Chicago, IL, 2Northwestern University, Chicago, 3University of Pittsburgh, Pittsburgh, PA, 4Northwestern University, Skokie, IL

    Background/Purpose: Unclear mechanisms underlying diffuse NPSLE (psychosis, anxiety disorder, cognitive dysfunction) may lead to the devastating impact of this disease on patients’ health-related quality-of-life, representing…
  • Abstract Number: 0317 • ACR Convergence 2024

    Progressive Fibrosing Intersticial Lung Disease of Autoimmune Origin and Antifibrotic Medication: NEREA Registry

    Pablo Moreno-Fresneda1, Cristina Vadillo-Font2, Fredeswinda Romero-Bueno3, Olga Sánchez-Pernaute4, Rosalía Laporta5, hildegarda Godoy Tundidor6, Belén López-Muñiz7, Laura Cebrián7, Claudia Valenzuela8, Irene Llorente-Cubas9, Jesús Loarce10, Juan Rigual10, Benjamin fernandez-Gutierrez11, M Asuncion Nieto1 and lydia Abasolo Alcazar12, 1Hospital Clínico San Carlos, Madrid, Madrid, Spain, 2Hospital Clinico S Carlos, Madrid, Spain, 3Hospital Universitario Fundación Jiménez Díaz and IIS-FJD. Autonomous University of Madrid, Madrid, Spain, 4Department of Rheumatology and Joint and Bone Research Unit. Hospital Universitario Fundación Jiménez Díaz and IIS-FJD. Autonomous University of Madrid, Madrid, Spain, 5Hospital Universitario Puerta de Hierro, Madrid, Spain, 6Servicio de Reumatología, Hospital Universitario Puerta de Hierro Majadahonda, IDIPHISA , Madrid, Madrid, Spain, 7Hospital Universitario Infanta Leonor, Madrid, Spain, 8ILD Unit, Pulmonology Department, Hospital Universitario de la Princesa, University Autonomade Madrid, Madrid, Spain, Madrid, Madrid, Spain, 9Hospital Universitario de La Princesa, Madrid, Spain, 10Ramón y Cajal University Hospital, Madrid, Madrid, Spain, 11HOSPITAL CLINICO SAN CARLOS, Madrid, Spain, 12IdISSC. HCSC, Madrid, Spain

    Background/Purpose: Nintedanib and pirfenidone are approved therapies for the management of patients with progressive fibrosing interstitial lung diseases (ILD), including those of autoimmune origin (ILD…
  • Abstract Number: 0054 • ACR Convergence 2024

    Supernatants from Macrophages Stimulated with Citrullinated and MAA-Modified Fibrinogen Contain PDGF-BB and TGF-b and Upregulate Fibrotic Markers in Human Lung Fibroblasts

    Nozima Aripova1, Michael Duryee1, Bryant England1, Carlos Hunter1, Lauren Klingemann1, Nigina Aripova2, Amy Nelson1, Jill Poole1, Dawn Katafiasz1, Kristina Bailey1, Geoffrey Thiele1 and Ted Mikuls1, 1University of Nebraska Medical Center, Omaha, NE, 2WUSTL, St. Louis, MO

    Background/Purpose: Lung tissues from patients with rheumatoid arthritis-associated interstitial lung disease (RA-ILD) have greater levels of malondialdehyde-acetaldehyde adducts (MAA) that co-localize with citrullinated (CIT) and…
  • Abstract Number: 0077 • ACR Convergence 2024

    Characteristics of Axial Spondyloarthritis in Patients with Onset Chronic Low Back Pain After Age 45

    Fatma Zohra Yasmina Heddi1, Zahira Lamri2, kheireddine khelif2, Amina Benammar2 and wafa Zahdour2, 1Oran University Hospital, Rheumatology Department/ University of Oran 1, Faculty of Medicine, Oran, Oran, Algeria, 2Oran University Hospital, Rheumatology Department/ University of Oran 1, Faculty of Medicine, Oran, Algeria

    Background/Purpose: The onset of axial spondyloarthritis (axSpA), as defined by the Assessment of SpondyloArthritis International Society (ASAS) criteria is unusual after the age of 45…
  • Abstract Number: 0385 • ACR Convergence 2024

    Cross-cultural Validation of the “Effects of Youngsters-Eyesight on Quality of Life (EYE-Q)”: A Measure of Vision-related Quality of Life and Function in Childhood Uveitis

    sheila Angeles-Han1, Jordi Anton2, Amra Adrovic3, Patricia Costa Reis4, Joke De Boer5, Séverine Guillaume-Czitrom6, Theresa Hennard7, Marija Jelusic8, Ozgur Kasapcopur9, Ilaria Maccora10, Hana Malcova11, Joseph McDonald12, Najima Mwase13, Gabriele Simonini14, Waheba Slamang15, Derrik du Toit16, Hendrike van Vollenhoven16 and Ivan Foeldvari17, 1Cincinnati Children's Hospital, Cincinnati, OH, 2Hospital Sant Joan de Déu. Universitat de Barcelona, Esplugues de Llobregat (Barcelona), Spain, 3Deparment of Pediatric Rheumatology, Istanbul University-Cerrahpasa, Istanbul, Turkey, 4Hospital de Santa Maria, Lisbon, Portugal, 5Department of ophthalmology, University Medical Center Utrecht, Utrecht, Netherlands, 6University Hospital of Bicetre, Kremlin-Bicêtre, France, 7Cincinnati Children's Hospital and Medical Center, Cincinnati, OH, 8University of Zagreb School of Medicine, University Hospital Centre Zagreb, Zagreb, Zagreb, Croatia, 9Istanbul University-Cerrahpasa, Cerrahpasa Medical School, istanbul, Turkey, 10?PhD student, in the Area of Drugs and Innovative Treatments, NeuroFARBA Department, University of Florence. Meyer Children's Hospital, Florence Italy, Firenze, Florence, Italy, 11FN Motol, Praha, Czech Republic, 12University of Chicago, Chicago, IL, 13Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 14Meyer Children Hospital IRCCS; NEUROFARBA Department, University of Florence, Florence, Italy, 15University of Cape Town, Department of Child and Adolescent Health, Cape Town, South Africa, 16Red Cross Children’s Hospital, Cape Town, South Africa, 17Hamburg Centre for Pediatric and Adolescence Rheumatology, Hamburg, Germany

    Background/Purpose: Childhood uveitis leads to sight-threatening complications in 50% of affected children and significantly impacts a child’s quality of life and function. The Multinational Interdisciplinary…
  • Abstract Number: 0036 • ACR Convergence 2024

    Deep Topic Modeling Deconvolves Cell States in Spatial Transcriptomic Profiles of Rheumatoid Arthritis Synovial Tissue

    Preethi Periyakoil1, Melanie Smith2, Meghana Kshirsagar3, Daniel Ramirez4, Edward Dicarlo5, Susan Goodman6, Laura Donlin2 and Christina Leslie7, 1Weill Cornell Medical College, New York, NY, 2Hospital for Special Surgery, New York, NY, 3Microsoft AI for Good, Seattle, 4Hospital for Special Surgery, Cartago, Costa Rica, 5Hospital for Special Surgery, Weill Cornell Medicine, New York, NY, 6Hospital for Special Surgery, New York 10025, NY, 7Memorial Sloan Kettering Cancer Center, New York, NY

    Background/Purpose: Recent single-cell RNA sequencing (scRNA-seq) studies of the rheumatoid arthritis (RA) synovium have highlighted the heterogeneity of cell states present during active disease. It…
  • Abstract Number: 0007 • ACR Convergence 2024

    Bromodomain 2 of BET Proteins Plays a Crucial Role in Follicular/peripheral Helper T Cell and Plasma Cell Differentiation

    Ryota Sato1, Mitsuhiro Akiyama2, Koichi Oshita3, Yuko Kawano3, Yuki Imura3, Piruzyan Mariam4, Manami Kikuchi3, Mikako Murase3, Sachiko Mochiduki3, Naohiro Hashimoto3, Masayuki Watanabe3, Keiko Yoshimoto5, Tsutomu Takeuchi6, Kenji Chiba7 and Yuko Kaneko5, 1Mitsubishi Tanabe Pharma Corporation, Brighton, MA, 2Keio University School of Medicine, Palo Alto, CA, 3Mitsubishi Tanabe Pharma Corporation, Yokohama, Japan, 4Mitsubishi Tanabe Pharma Corporation, Yokohama, Kanagawa, Japan, 5Keio University School of Medicine, Tokyo, Japan, 6Department of Internal Medicine, Keio University, Tokyo, Tokyo, Japan, 7Mitsubishi Tanabe Pharma Corporation, Tokyo, Japan

    Background/Purpose: Proteins motifs bromodomain 1 (BD1) and BD2 within the BET family proteins regulate gene expression of inflammatory cytokines and lymphocyte proliferation by binding to…
  • Abstract Number: 0013 • ACR Convergence 2024

    Preclinical Polypharmacology of S-1117, a Novel Engineered Fc-fused IgG Degrading Enzyme, for Chronic Treatment of Autoantibody-mediated Diseases

    Julia Manasson1, Liliana Sanmarco2, Alex Pellerin2, Jordan Anderson2, Nathan Rollins2, Tobias Green2, Agustin Plasencia2, Andita Newton2, Ryan Peckner2, Yi Xing2, Heather Vital3, Nathan Higginson-Scott2, John Sundy4, Kevin L. Otipoby2 and Ivan Mascanfroni2, 1Seismic Therapeutic, New York, NY, 2Seismic Therapeutic, Watertown, MA, 3Seismic Therapeutic, Lexington, MA, 4Seismic Therapeutic, Chapel Hill, NC

    Background/Purpose: Pathogenic autoantibodies are key effectors of inflammation, promoting immune cell responses that cause tissue damage in autoantibody-mediated diseases such as idiopathic inflammatory myopathies, lupus…
  • Abstract Number: 0099 • ACR Convergence 2024

    Modulating Pentose Phosphate Pathway Metabolism to Temper Neutrophil Hyperactivity in Antiphospholipid Syndrome

    Kaitlyn Sabb1, Ajay Tambralli1, Megan Radyk1, Emily Becker1, Srilakshmi Yalavarthi1, Claire Hoy1, Cyrus Sarosh2, Jacqueline Madison1, Yu Zuo1, Costas Lyssiotis1 and Jason Knight1, 1University of Michigan, Ann Arbor, MI, 2University of Michigan, Temperance, MI

    Background/Purpose: Neutrophil hyperactivity and neutrophil extracellular trap (NET) release (NETosis) appear to play important roles in antiphospholipid syndrome (APS) pathogenesis. To kill microbes and propel…
  • Abstract Number: 0108 • ACR Convergence 2024

    Phenotypic Characterization of Patients with IgM Antibodies in Antiphospholipid Syndrome (APS)

    Fernanda Oliveira de Andrade Lopes1, Andreia Coimbra Sousa2, Massimo Radin3, Gustavo Balbi4, Irene Cecchi3, Savino Sciascia5, Flavio Victor Signorelli6 and Danieli Andrade2, 1Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil, São Paulo, SP, Brazil, 2University of São Paulo, São Paulo, SP, Brazil, 3University of Turin, Turin, Italy, 4Universidade Federal de Juiz de Fora, Juiz de Fora, Minas Gerais, Brazil, 5University of Turin, Torino, Turin, Italy, 6Universidade do Estado do Rio de Janeiro, Rio De Janeiro, Brazil

    Background/Purpose: Antiphospholipid syndrome (APS) is characterized by the presence of antiphospholipid antibodies (aPL) associated with thrombosis and/or pregnancy morbidity. Although the presence of lupus anticoagulant…
  • « Previous Page
  • 1
  • …
  • 24
  • 25
  • 26
  • 27
  • 28
  • …
  • 2425
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology